(MTCR) – FDA
-
Metacrine (MTCR) Reports Topline Results for MET409 Phase 2a Combination Trial
-
Metacrine (MTCR) Announces Interim Results for MET642 Phase 2a Trial in Patients with NASH; Announces Strategic Re-Prioritization of Its Clinical Development Programs
-
-
-
-
-
-
-
Back to MTCR Stock Lookup